RxDoctor Payments Data

Nirav Jasani, MD

Nephrology · Wilson, NCNPI 1215229612

Payments from drug & device makers

$15,001in general payments, 2019–2025

Across 786 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Johnson & Johnson$881
  • Bayer$847
  • OPKO Pharmaceuticals, LLC$717
  • plus $9K from 37 others

What the payments were for

  • Food & beverage$14,48597%
  • Education$5163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,001 in reported general payments places this provider in the 80th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$152,834
Medicare patients
297
Services billed
1,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin261$218,387
FarxigaDapagliflozin Propanediol223$158,336
VelphoroSucroferric Oxyhydroxide13$41,837
RayaldeeCalcifediol24$32,530
RybelsusSemaglutide22$32,526
OzempicSemaglutide22$31,579
AuryxiaFerric Citrate20$29,151
VeltassaPatiromer Calcium Sorbitex26$25,966
TradjentaLinagliptin23$24,181
KerendiaFinerenone30$24,097
EliquisApixaban34$21,683
JanuviaSitagliptin Phosphate13$15,848
XareltoRivaroxaban23$14,242
Sevelamer Carbonate56$14,021
Humulin R U-500 KwikpenInsulin Regular, Human12$13,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,228$242,568284 claims
AstraZenecaFarxiga$1,090$158,336223 claims
Novo NordiskRybelsus, Ozempic$711$64,10544 claims
Fresenius USA Marketing, Inc.Velphoro$362$41,83713 claims
OPKO Pharmaceuticals, LLCRayaldee$717$32,53024 claims
Akebia Therapeutics IncAuryxia$503$29,15120 claims
BayerKerendia$847$24,09730 claims
PfizerEliquis$268$21,68334 claims
MerckJanuvia$414$15,84813 claims
Johnson & JohnsonXarelto$881$14,24223 claims
GSKBreo Ellipta, Incruse Ellipta$338$13,12833 claims
ANI Pharmaceuticals, Inc.Valsartan$80$79541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Wilson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →